Harbour Antibodies

Harbour Antibodies owns two world-leading transgenic mouse platforms for fully human antibody development, HCAb and H2L2. The licensee companies of the platforms are conducting multiple drug research and development projects, with the most advanced antibody candidate expected to enter clinical development in 2017.